 | Up a level |
Granholm, Anders; Kjær, Maj-Brit Nørregaard; Munch, Marie Warrer; Myatra, Sheila Nainan; Vijayaraghavan, Bharath Kumar Tirupakuzhi; Cronhjort, Maria; Wahlin, Rebecka Rubenson; Jakob, Stephan M; Cioccari, Luca; Vesterlund, Gitte Kingo; Meyhoff, Tine Sylvest; Helleberg, Marie; Møller, Morten Hylander; Benfield, Thomas; Venkatesh, Balasubramanian; Hammond, Naomi E; Micallef, Sharon; Bassi, Abhinav; John, Oommen; Jha, Vivekanand; ... (2022). Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia. Intensive care medicine, 48(5), pp. 580-589. Springer 10.1007/s00134-022-06677-2
Granholm, Anders; Munch, Marie Warrer; Myatra, Sheila Nainan; Vijayaraghavan, Bharath Kumar Tirupakuzhi; Cronhjort, Maria; Wahlin, Rebecka Rubenson; Jakob, Stephan M; Cioccari, Luca; Kjær, Maj-Brit Nørregaard; Vesterlund, Gitte Kingo; Meyhoff, Tine Sylvest; Helleberg, Marie; Møller, Morten Hylander; Benfield, Thomas; Venkatesh, Balasubramanian; Hammond, Naomi E; Micallef, Sharon; Bassi, Abhinav; John, Oommen; Jha, Vivekanand; ... (2022). Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive care medicine, 48(1), pp. 45-55. Springer 10.1007/s00134-021-06573-1
